



Continuing Medical Education
Yale CME

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Metformin and maldigestion: Is intraluminal protease inhibition a previously unrecognized medication effect?

Caleb J. Kelly, MD, PhD

Gastroenterology Fellow, Department of Medicine (Digestive Diseases)
Yale School of Medicine

Tuesday, November 29, 2022
5:00 pm - 6:00 pm

<https://yale.zoom.us/j/96291471270?pwd=c2cwSnIrbjMzaGVVRZ2hrT05LYldsUT09&from=addon>

Host: Fred Gorelick, MD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (35291) to 203-442-9435.

There is no corporate support for this activity. **Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Metformin is one of the most prescribed medications owing to its effectiveness in treating type II diabetes, safety, low cost, and weight-loss-promoting effects. Gastrointestinal intolerance is the most common reason for not achieving the goal dose. Long-term use of metformin is also associated with vitamin B12 deficiency. Understanding the gastrointestinal and nutritional effects of metformin is important for clinicians in gastroenterology and hepatology who are likely to encounter metformin in clinical practice. Recent research will be presented that couples clinical observations with pharmacokinetic modeling and basic science experiments in the exploration of maldigestion as a potential consequence of metformin use. **Objectives:** Recognize the typical symptoms of metformin gastrointestinal intolerance; Understand the relationship between metformin dose, formulation, and concentration in the intestinal lumen; Appreciate the use of preclinical research in the exploration of clinical phenomena. **Faculty Disclosures:** None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**